NeuroTrauma Sciences

Focus: NeuroTrauma Sciences is a public biotech company focused on stroke and traumatic brain injury therapies, operating from Alpharetta, Georgia since 2016. The company is in early-stage development with a sparse pipeline and currently has zero active job openings.

Neurology Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About NeuroTrauma Sciences

AI assessmentNot Hiring

No open roles listed right now. Follow NeuroTrauma Sciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Physiotherapy

Chronic Conditions

N/A

Clinical Trials (1)

NCT00859638I Am Able: Population Based Rehabilitation in a Family Health Team

N/A

Help build intelligence for NeuroTrauma Sciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage biotech focused on high-unmet-need neurotrauma indications (stroke, TBI, spinal cord injury) with potential for significant impact
Public company status provides liquidity and access to capital markets for continued development
Emerging portfolio includes both small-molecule (NTS-104 TRIS) and non-traditional modalities (probiotics, digital therapeutics)

Watch Out For

Zero current job openings signal minimal hiring activity and potential restructuring or capital constraints despite public status
Pipeline is heavily early-stage (2 Phase 1 programs, 1 Phase 3) with unconventional comparators (placebo diet) raising questions about clinical strategy and regulatory feasibility
No revenue, no published clinical data (0 publications), and unknown financial health create existential execution risk

Generated by Claude from NeuroTrauma Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Placebo Diet

Spinal Cord Injury

N/A

Clinical Trials (1)

NCT04271904Effect of Sham Anti-inflammatory Diet on Inflammation After Spinal Cord Injury

N/A

NTS-104 TRIS

Acute Ischemic Stroke

Phase 1

Probiotic Lactobacillus GR-1 and RC-14

Spinal Cord Injury

Phase 1